SCHEMBL20047538

SCHEMBL20047538

CC(C)c1cccc2cc(F)c(C(C)(C)C)nc12

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP1A2 P05177 2/20 0.39
▸ CYP3A4 P08684 2/20 0.39
▸ HPGD P15428 2/20 0.39
▸ TSHR P16473 2/20 0.39
▸ KDM4E B2RXH2 1/20 0.39
▸ ALDH1A1 P00352 1/20 0.39
▸ GLA P06280 1/20 0.39
▸ CYP2C19 P33261 1/20 0.39
▸ HSD17B10 Q99714 1/20 0.39
▸ LMNA P02545 3/20 0.38
▸ GABRA1 P14867 2/20 0.32
▸ GABRG2 P18507 2/20 0.32
▸ GABRB3 P28472 2/20 0.32
▸ FAAH O00519 1/20 0.32
▸ CA1 P00915 1/20 0.32
▸ CA2 P00918 1/20 0.32
▸ GABRB1 P18505 1/20 0.32
▸ PTGS1 P23219 1/20 0.32
▸ SLC6A2 P23975 1/20 0.32
▸ HTR2C P28335 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20043238 0.79 CA2 (0.35) TSHRALDH1A1GABRA1CA2GABRB2
SCHEMBL25519641 0.79 GABRA1 (0.44) CYP1A2CYP3A4HPGDTSHRKDM4E
SCHEMBL20047582 0.77 BCL2L11 (0.34) CYP1A2CYP3A4HPGDTSHRKDM4E
SCHEMBL20047489 0.71 GAA (0.36) CYP1A2CYP3A4HPGDTSHRKDM4E
SCHEMBL20047456 0.70 CCR4 (0.40) CYP1A2CYP3A4HPGDTSHRKDM4E
SCHEMBL24721913 0.70 PSMD14 (0.39) CYP1A2CYP3A4HPGDTSHRKDM4E
SCHEMBL16144462 0.69 ALDH1A1 (0.46) CYP1A2HPGDKDM4EALDH1A1GLA
SCHEMBL1186316 0.68 HPGD (0.50) CYP1A2CYP3A4HPGDTSHRKDM4E
SCHEMBL20047610 0.67 NPC1 (0.34) KDM4EALDH1A1HSD17B10LMNAPTGS1
SCHEMBL28244025 0.66 PDE3B (0.40) TSHRKDM4EALDH1A1HSD17B10MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10450306-B2 Isoxazole analogs as FXR agonists and methods of use thereof ENANTA PHARMACEUTICALS, INC. (US) 2019-10-22 — — US disclosed
US-20180099957-A1 ISOXAZOLE ANALOGS AS FXR AGONISTS AND METHODS OF USE THEREOF ENANTA PHARMACEUTICALS, INC. 2018-04-12 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10450306-B2 Isoxazole analogs as FXR agonists and methods of use thereof GPBAR1, SLC10A1, NR1H4 CYP1A2 311/4885CYP3A4 418/4885HPGD 651/4885
US-20180099957-A1 ISOXAZOLE ANALOGS AS FXR AGONISTS AND METHODS OF USE THEREOF GPBAR1, SLC10A1, NR1H4 CYP1A2 311/4885CYP3A4 418/4885HPGD 651/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback